AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tim Knotnerus
- Full Time Employees
- 62
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Posthoflei 1/6 Antwerp VL Belgium 2600
- IPO Date
- Feb 6, 2026
- CIK
- 0002020932
- Website
- agomab.com
- Similar Companies
- Business
- AgomAb Therapeutics N.V. American Depositary Shares, a Belgium-based clinical-stage biopharmaceutical company, focuses on developing disease-modifying therapies for immunology and inflammatory diseases with an emphasis on fibrotic indications and unmet medical needs. The company advances a focused pipeline of novel monoclonal antibodies and small molecules designed to modulate fibrosis pathways, including AGMB-101, an HGF-mimetic antibody targeting MET signaling to promote antifibrotic and regenerative effects; AGMB-129, an ALK-5 inhibitor aimed at fibrostenotic Crohn’s disease; and additional preclinical programs targeting fibrosis, inflammatory, and metabolic conditions. AgomAb retains exclusive worldwide development and commercialization rights for all product candidates and preclinical programs. Founded in 2017, the company is headquartered in Antwerp, Belgium, with its corporate structure organized as a cross-border, clinical-stage biotechnology entity pursuing global development and strategic collaborations. AgomAb pursues partnerships and financing to accelerate clinical progression, expand its pipeline, and broaden its global reach across immunology and fibrotic diseases. The company’s operating activities cover research and development, preclinical and translational studies, and early-phase clinical trials, with a business model oriented toward forging strategic alliances, securing milestone-driven funding, and building a diversified portfolio of disease-modifying therapies. AGMB aims to establish a commercial footprint in major markets through collaborations and potential future U.S. and European listings to support regulatory submissions and product launches.
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease
AgomAb Therapeutics: High Risk, High Reward Stock
Agomab Announces Results of Annual General Meeting
Agomab Announces Results of Annual General Meeting
Agomab to Participate in Upcoming Conferences
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
Agomab Announces Closing of Initial Public Offering
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Market Today: Dow tops 50,000 as chip leaders rebound; Stellantis plunges
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Agomab Announces Pricing of Initial Public Offering
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
AgomAb Therapeutics NV Readies US IPO On Early Promising Results
Agomab Therapeutics files for US IPO